An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects

Trial Profile

An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Darapladib (Primary)
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Jul 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top